http://www.neotechvaccines.com
NEOTECH has and is developing some of the pet industry's finest and most effective canine vaccines. Our premier vaccine, NEOPAR®, is the only vaccine on the market today that combats all known strains of the deadly Canine Parvovirus. NEOPAR® was co-developed at the height of one of the nation's worst epidemics of Parvo by Dr. Bob Page of Dresden, TN. Dr. Page is also the owner and founder of NEOTECH, LLC. Today, Dr. Page and NEOPAR® are two of the greatest assets to every dog owner. Dr. Page travels all over the country to promote better Canine care.
IMMVAC, Inc. was founded in 1984 by its two principal owners, Dr. Ronald Sprouse, a former Professor of Pathology at the University of Missouri School of Medicine, and his wife, Dorothy. Located in Columbia, Missouri, IMMVAC, Inc. manufactures vaccines and serums for production and companion animals to aid in the protection and treatment of virtually all gram-negative bacteria. IMMVAC products are based on two exclusively-owned core technologies: 1) a patented genetically-engineered gram-negative mutant Bacterin, Re 17, which is comprised of the universal core antigen common to all gram-negative bacteria; and 2) a patented immunopotentiator, E3, which stimulates production of T- and B-lymphocytes, thereby enhancing an animal's overall immunity to disease.
Beijing Tiantan Biological Products Corporation Limited is engaged in the biopharmaceutical industry. The Company's products include vaccines, blood-related products and disease diagnostic solutions. During the year ended December 31, 2007, the Company obtained approximately 82% and 17% of its total revenue from vaccines and blood-related products, respectively. The Company distributes its products mainly in the domestic market. As of December 31, 2007, the Company had two major subsidiaries and associate. The Company is headquartered in Beijing, China. (Source: ARS)
Today, PHL produces a variety of products to protect and accommodate many different species. Also, custom-made autogenous vaccines can be produced to fit your specific needs. Because PHL isn't a huge conglomerate, we're able to give our customers the personal attention required to address their specific needs. We realize that the health of your animals is extremely important to you. You deserve the focused attention that only PHL can provide. Whether it's a product we already produce, or one that we develop especially for you, expect the quality service we've provided for 45 years. PHL's laboratory is located in Davis, California. It is there that the research, development and manufacturing takes place. We also have a separate office in Sacramento, California, which specifically handles customer service of all kinds. Here at PHL, we pride ourselves on our excellent customer service. Whether you're a brand new client, or a long-established one, we'll do our very best to handle your specific needs. If you need to speak to our experienced veterinarians or simply reorder a product, our staff is always available and ready to help. Our customer service department is available from 9 a.m. to 5 p.m. (Pacific Time), five days a week, and can be reached on our toll-free number, 1-877-566-7722. You may email us, if you prefer, at info@phlassociates.com. Please contact us so we may give you the information and attention you need. Whatever you require, we will continue to provide the most comprehensive, tailor-made service available anywhere. PHL was established in 1960 by Dr. Robert Wichmann, the first to develop the Parvo vaccine for canines. We follow the most stringent laboratory procedures to produce the purest, most efficacious vaccines and biologicals available. Our products are produced and shipped in a timely manner. Quality control is of utmost importance and is personally overseen by our staff of qualified DVM's/PhD's.
Veterinary Technologies Corporation (VetTek) was founded in 1993 and focuses on the application of biotechnology in the development of vaccines, diagnostics and biowaste handling which address the health needs of animals and humans throughout the world. It also offers consulting services and workshops in the areas of biotechnology, microbiology and immunology. The company has four principals which direct the overall operation of the company as well as other staffers. It has offices and laboratory facilities at the Virginia Tech Corporate Research Center in Blacksburg, Virginia.
http://www.networkimmunologyinc.com
Network Immunology Inc. is a vaccine company. The company's focus is to commercialize a preventive HIV vaccine invented in 2005 by Dr. Geoffrey W. Hoffmann, the Chief Scientist of the company. The Network Immunology vaccine is for HIV negative persons. The technology is based on a theory of AIDS pathogenesis developed by Dr. Hoffmann (G. W. Hoffmann (1994) Co-selection in immune network theory and in AIDS pathogenesis, Immunology and Cell Biology, 72, 338-346). A key postulate of the theory was validated in a paper published eight years later (D. C. Douek et al. (2002) HIV preferentially infects HIV-specific CD4+ T cells. Nature, 417, 95-98). The global demand for an HIV/AIDS vaccine ia massive. Each year, approximately 5 million people become infected with HIV, and there are currently over 40 million HIV positive people worldwide.
EQiTX Limited (ASX Code - EQX) is an Australian public biotechnology company dedicated to the commercial research and development of new therapeutic drugs for chronic diseases and conditions affecting the aging population. The company is acquiring and maturing a portfolio of technologies, with the potential to develop more than a single product that is commercially attractive to multinational biotechnology and pharmaceutical companies. The acquired technologies have passed a rigorous and selective review process, significantly increasing their likelihood of commercial success. The EQiTX team - comprising the Board, Executive, Advisory Board and consultants - have a wealth of domestic and international experience in technology transfer, management and science, law, corporate governance and financial management. In particular, EQiTX has engaged people who have first hand industry experience spanning the in-licensing of technologies for multinational pharmaceutical and life-science companies, as well as the management of commercial Research and Development programmes. This provides the company with a detailed knowledge about which technologies will be attractive to multinational pharmaceutical companies, and which commercial Research and Development activities should be supported. EQiTX's preferred business model is to place each acquired technology into a new company ('Newco'), holding 100% of the rights to exploit the intellectual property. The 'Newco' ventures will have the capacity to either individually list on an appropriate stock market, or provide financial returns through licensing arrangements or a trade sale to a large biotechnology or pharmaceutical company.
The name "Grand Laboratories" originated when I was an instructor at the veterinary school in Ames, Iowa and lived near Grand Ave. During this time, I developed and began producing serveral equine-origin antiserums- the first Grand biologicals. In a relatively short span of years, Grand Laboratories, Inc. had made an impressive impact on the veterinary biological industry. Our products have become vital aids in helping veterinarians prevent and treat the animal health problems of modern livestock producers. Our unique innovative immunological concepts are unparelled in the industry. Grand Laboratories, Inc. is committed to your success and prosperity. Every innovation and technological advance Grand has pioneered over the years was developed specifically to benefit the veterinary practitioner... to help you effectively and profitably serve your clients. From this modest beginning, Grand has grown into the company we are today. I attribute Grand's success to God's blessing and to you, our veterinary customers.
Microtek International Inc. and Microtek Research and Development Ltd. develop, manufacture and market advanced health products and services to the world's fastest-growing agriculture sector, aquaculture since 1983. In particular, Microtek serves the aquaculture industry across Canada, the U.S.A., Chile, Norway and other European countries. Microtek uses proprietary and patented technologies to deliver market-leading aquaticvaccines and diagnostics, and is developing innovative oral and viral vaccines. The company is experienced in all aspects of Microbiology and Biochemistry, including: development of vaccines and diagnostics; alternative methods of drug delivery; and monoclonal and polyclonal antibody production. Microtek also offers fish health services with diagnostic techniques including ELISA, immunofluorescence assays, tissue culture, and genetic techniques. Microtek maintains an extensive research network including an alliance with the University of Victoria, University of British Columbia, National Research Council (Institute for Marine Biosciences), Oregon State University, Mississippi State University, Massachusetts Institute of Technology, Maine Biotek Inc., and the University of Berne (Switzerland). Microtek utilizes Bayer as a global distributor.
Shire Pharmaceuticals Group plc (Shire) is a global specialty pharmaceutical company with a strategic focus on meeting the needs of the specialist physician and currently focuses on developing projects and marketing products in the areas of central nervous system (CNS), gastrointestinal (GI), and renal diseases. Shire has operations in the world's key pharmaceutical markets (US, Canada, UK, France, Italy, Spain and Germany) as well as a specialist drug delivery unit in the US.
Cambridge Biostability Limited based in Cambridge, UK, has developed a revolutionary technology, which reformulates existing vaccines into ready-to-inject stable liquids requiring no refrigeration or reconstitution. The company has a portfolio of patents and is entering into a number of agreements to licence and provide outsourced production of 'stable liquid' vaccines. The CBL technology is based on a process called anhydrobiosis, which is widespread in nature. Some organisms are able to survive drought in a dried-up form for hundreds of years. Water within the cells contains sugar. This thickens to a syrup as water is removed to a point of solidifying as a glass when the organism dries out. Cells are kept in a state of suspended animation, embedded in the glass until re-hydration occurs and dissolves the glass and the organism - plant, animal or bacteria - returns to life. This process is being applied for the first time to vaccines. Soluble-glass-forming agents harden to form a non-crystalline glass. So the vaccine is first spray-dried to form microscopic glass spheres. The dry vaccine is then suspended in an approved inert liquid, which can be injected where bodily fluids reactivate the vaccine. Since the CBL stable liquid formulations are anhydrous, they are inherently bacteriostatic, as bacteria require water to multiply. Thus the need for antiseptics such as thiomerosal is eliminated. Several vaccines, including hepatitis B, Hib Meningitis A and tetanus toxoid, have already been prepared using stable liquid technology.
Since 1949, Wyeth Animal Health has been synonymous with quality and performance in vaccines and pharmaceuticals for companion animals, livestock and horses. Headquartered in Guelph, Ontario, Wyeth Animal Health's 60 employees provide Canadian veterinarians with products to help them fight disease and maintain the health of Canada's animals. Innovative products distributed by Wyeth Animal Health include: West-Nile Innovator; Duramune®; Cydectin Pour-On®; the Suvaxyn®, Pyramid® and Triangle® vaccine lines; and Quest Gel®. Our parent company, Fort Dodge Animal Health, is a leading manufacturer and distributor of animal health care products for both livestock and companion animals. Fort Dodge Animal Health serves Canada, the United States and international markets, distributing products in more than 100 countries. It is one of the leading veterinary vaccine manufacturers in the world and ranks second in veterinary vaccine sales in North America. The divison's ability to research and develop new, innovative products and deliver them to the marketplace is highly respected in the field. No animal health company offers a wider range of proven vaccines, pharmaceuticals, education and technologies. Fort Dodge Animal Health is recognized for its breakthroughs in veterinary medicine. Our dedication to product development continues to strengthen our reputation as a proven leader in the animal health industry. Today, Fort Dodge Animal Health has nearly 3,500 employees worldwide with nearly 2,000 employees in North America. The division established worldwide headquarters in Overland Park, Kansas, in 1995. The move to the Kansas City suburb followed the acquisition of the American Cyanamid Company and Syntex Animal Health and allowed the company to centralize its rapidly growing operations.
http://www.henderson-morley.com
Henderson Morley were formed in 1996, and have been listed on the London Stock Exchange (AIM) since 2001. The company has established a state of the art research facility in Birmingham UK, with comprehensive virus culture and research facilities. These have yielded some important medical breakthroughs leading to several licensing deals with pharmaceutical company partners, and the granting of over 20 patents.
Pharmexa is a leading company in the field of active immunotherapy and vaccines for the treatment of cancer, serious chronic and infectious diseases. Pharmexa's proprietary technology platforms are broadly applicable, allowing the company to address critical targets in cancer and chronic diseases, as well as serious infectious diseases such as HIV, influenza, hepatitis and malaria. Pharmexa's leading programs are GV1001, a peptide vaccine that has entered phase III trials in pancreatic cancer and phase II trials in liver cancer, and HIV and hepatitis vaccines in phase I/II. Collaborative agreements include H. Lundbeck, Genimmune (subsidiary of Innogenetics), IDM Pharma and Bavarian Nordic. With operations in Denmark, Norway and USA, Pharmexa employs approximately 105 people and is listed on the Copenhagen Stock Exchange under the trading symbol PHARMX.
BioDiem Ltd. operates in the biopharmaceutical industry developing and commercializing biomedical research. The Company has acquired a license to commercialize influenza vaccine technologies from the Institute of Experimental Medicine. The Company’s live attenuated influenza vaccine (LAIV) was licensed in Noblin International. BioDiem, through its collaboration with the IEM continues to complete research characterizing the benefits of LAIV for the treatment of influenza. The Company has obtained the rights through an option to take a license to a synthetic peptide BDM-E, for the treatment of retinal eye diseases. (Source: ARS)
Pfizer Canada's Community Investment Program is dedicated to improving the health and quality of life of Canadians by investing in our communities, with particular emphasis on healthcare as well as health and science education. In 2006, Pfizer Canada, the leader of the research-based pharmaceutical industry, invested over $20 million in more than 1,000 non-profit organizations and projects across Canada in the following six major areas: Corporate Philanthropy, Science and Health Education, Disease Awareness, Local Communities, Scientific and Academic Community and Product Donations. In addition, Pfizer Canada has a Matching Gift Program in place which matches contributions made by its employees. This means that whether an employee donates $100 a year to his/her Alma Mater or raises $75 for a fundraising walk or run, the recipient organization receives double that amount. We invite you to learn more about our funding criteria and guidelines before submitting a request for support. Pfizer Canada produces a Community Investment Brochure. If you would like to download it, click here.
GenPhar, Inc. is a biopharmaceutical company dedicated to becoming a leader in developing and producing prophylactic and therapeutic vaccines to protect against the world's most dangerous diseases. To reach its goals, GenPhar will leverage the advantage of its proven safe and effective ProVax and TheraVax vaccine platforms -- unique technology capable of producing multiple vaccine products. GenPhar's products are divided into two main areas: vaccines for biodefense and vaccines for chronic infectious diseases (including HIV, hepatitis B and hepatitis C). These products will have a large scale socio-economic impact and transformative effect on current research and treatments. GenPhar was founded in 1999 and is headquartered in Mount Pleasant, South Carolina. To learn more about GenPhar and its vaccine programs, please contact us.
Medicago, a world leader in plant-made pharmaceuticals, uses alfalfa plants as living, bio-safe factories to deliver high-value active elements to the human health, cosmeceutical, industrial sectors and numerous others. Located in Québec City, Medicago offers a French dynamic working environment with high-tech offices and equipment, competitive salaries, a health plan and a stock option program. Medicago offers interesting career opportunities in the following fields: Agronomy Molecular biology, cellular or agricultural Biochemistry Analytical chemistry In-vitro culture Microbiology Protein purification Administration If you are a dynamic, motivated and skillful person, ready to face the many challenges of our high-tech business sector, don't hesitate to send us your resume. Until a position opens up, we will confidentially keep your resume in our files for a period of 6 months. If you wish to submit your application, don't hesitate to send your resume by mail, fax or email at the following address: MEDICAGO inc. Human resources services 1020, route de l'Église Sainte-Foy (Québec) G1V 3V9 Fax: (418) 658-6699 Email: rh-hr@medicago.com We hope that you will add this page to your « favorites » in order to regularly consult the posted details of available positions during our recruitment process. Medicago is an equal opportunity employer. We thank you for your resume, however, please take note that only the persons selected for an interview will be contacted.
QSV Biologics, Ltd. is a North American based cGMP biologics contract manufacturer providing mammalian cell culture, microbial fermentation and purification services for the production of protein therapeutics, monoclonal antibodies, vaccines and diagnostics. Our facility has a 10 year track record and is licensed for cGMP manufacture of pre-clinical, clinical and commercial supply. QSV recently underwent a comprehensive GMP compliance audit by Health Canada's Health Products and Food Branch Inspectorate (HPFBI) and was found to be compliant with all applicable regulations and guidelines. QSV's market consists of Canadian, U.S., Australian, Asian and European biotechnology firms with protein therapeutics in development. As a dedicated biopharmaceutical contract manufacturer, QSV provides the following services: cGMP Microbial Fermentation Microbial Process Development Upstream and Downstream Mammalian Cell Culture Process Development Upstream and Downstream cGMP Cell Bank Development & Storage Analytical Development Process & Analytical Validation Process Scale Up cGMP Document Services Technology Transfer Quality is your first consideration when selecting a contract manufacturer. Quality is our first priority! More information can be obtained by contacting: Richard Hetrick Business Development Phone: (484) 678 - 4820 Phone: (780) 438 - 7143 Fax: (610) 873 - 8453 Email: rhetrick@qsvbiologics.com
Privacy Policy | Terms and Conditions | Do Not Sell My Personal Information | Websites Directory
Copyright © 2022 kwtbox.com. All Rights Reserved. US Business Directory